4 people out of 100 who received the placebo experienced a heart attack after 3 years
Keywords , NAFLD , non-alcoholic fatty liver disease , non-alcoholic cirrhosis , cirrhosis , steatotic liver disease , cardiovascular risk , cardiovascular disease 0 3 INTRODUCTION Metabolic dysfunction-associated steatotic liver disease (MASLD), is currently a leading cause of chronic liver disease globally [1-4]
Semaglutides extended-release (ER) formulation provides a prolonged half-life compared to short-acting GLP-1 RAs, supporting once-weekly dosing regimens and enhancing patient adherence (23)(32)
Personalized Approach : Every treatment plan is tailored to your specific health needs and weight loss goals
This practice is legal but controversial
However, side effects such as fatigue, reduced energy, and muscle lossespecially during rapid weight losscan make workouts feel more difficult